The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Atacand Plus 8 mg/12.5 mg tablets

8 mg/12.5 milligram(s) Tablet

AstraZeneca ABPA1019/005/001

Main Information

Trade NameAtacand Plus 8 mg/12.5 mg tablets
Active SubstancesCandesartan cilexetil
Hydrochlorothiazide
Strength8 mg/12.5 milligram(s)
Dosage FormTablet
Licence HolderAstraZeneca AB
Licence NumberPA1019/005/001

Group Information

ATC CodeC09DA Angiotensin II antagonists and diuretics
C09DA06 candesartan and diuretics

Status

Authorised/WithdrawnAuthorised
Licence Issued27/11/1998
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0029-058-002
Interchangeable List DocumentPDF of Interchangeable List
« Back